-+ 0.00%
-+ 0.00%
-+ 0.00%

BRIEF-Revolution Medicines' New Drug Application For Daraxonrasib Accepted For Review By U.S. FDA

路透·07/22/2026 22:01:20

登錄查看新聞詳情